Brexafemme®
Drugs - Brexafemme® (ibrexafungerp) [Scynexis, Inc.]
April 2022
Therapeutic area - Antifungals, Oral
Initial approval criteria
- Patient must have a diagnosis of vulvovaginal candidiasis AND
- Patient is not pregnant AND
- Patient is at least 18 years of age or patient is less than 18 years of age and post menarche AND
- Patient has tried and failed a trial of oral fluconazole, unless contraindicated for the current episode
Quantity limits
- 4 tablets per day per treatment
Questions?
MHCP Provider Resource Center 651-431-2700 or 800-366-5411